



# ALLIANCE E-NEWS

FALL 2015 | VOLUME 5, NUMBER 6

## **Message From the Group Chair**

### **'An Exciting, Productive Year!'**



Monica Bertagnolli, MD

The past year has been an exciting and productive one for our group. Perhaps the most gratifying is a substantial increase in accrual to Alliance studies - a 25 percent increase over last year! Publications, which represent the final product of all our efforts, remain strong, and our committees continue to produce exciting new study designs addressing a wide spectrum of cancer treatment, control, and translational research concerns. [Read more](#)

## **Introducing New Alliance Group Vice-Chair**

## Suzanne George, MD

Dr. George, a leading medical oncologist and expert in sarcoma management and clinical investigation, has been appointed

the new Vice-Chair of the Alliance for

## Clinical Trials in Oncology by the

MEETINGS

2016 - Spring & Fall

- May 12-14 | Chicago
  - November 2-4 | Chicago

2017 - Spring & Fall

- May 11-13 | Chicago
  - November 2-5 | Chicago

## ANNOUNCEMENTS

## Alliance Names Three Most Notable, Original Manuscripts

## Alan Lyss Receives 2015 RLS CALGB Achievement Award + Annual Alliance Scholar Foundation Awards


## Alliance Patient Advocate Committee Update

## Alliance Data Management

### Consolidation

**Visit our website**

Learn more about what's happening in the Alliance, visit the [Alliance website](#) today!



Suzanne George, MD

Alliance Board of Directors during the recent 2015 Alliance Fall Group Meeting held in Chicago. Dr. George succeeds Edith A. Perez, MD, who is now Vice President and Head of Genentech/Roche BioOncology U.S. Medical Affairs.  
[Read more and meet other new leaders](#)

## Stay Connected

[Like us on Facebook](#) 

[Follow us on Twitter](#)

[Join Our Mailing List!](#)

## Statistics & Data Unit Leadership

### New Director for Statistics Xiaofei Wang, PhD

Dr. Wang has been named Director for Statistics for the Alliance Statistics and Data Center. He was previously Associate Director for Statistics.

Dr. Wang is currently an Associate Professor of Biostatistics and Bioinformatics at Duke University School of Medicine and a member of Duke Cancer Institute (DCI).



Xiaofei Wang, PhD

[Read more and meet other leaders](#)

## Recognition & Honors

### Alliance Receives the *CEO Roundtable on Cancer's Dr. Charles A. Sanders Life Sciences Award*



Christopher A. Viehbacher, Immediate Past Chairman, CEO Roundtable on Cancer; Dr. Monica Bertagnoli, Group Chair, and Dr. Dan Sargent, Group Statistician, both of the Alliance.

The Alliance for Clinical Trials in Oncology recently received the **2015 Dr. Charles A. Sanders Life Sciences Award** from the CEO Roundtable on Cancer in recognition of its innovative and

collaborative work on Project Data Sphere, LLC, an independent not-for-profit initiative of the CEO Roundtable on Cancer's Life Sciences Consortium. [Read more](#)

---

## **Spotlight on Trials**

### **First Targeted AML Therapy Significantly Improves Survival**

Acute myeloid leukemia (AML) is one of the most common forms of adult leukemia. Most of the approximately 30 percent of AML patients whose leukemia cells have a mutation in the FLT3 gene have a particularly poor prognosis, as their disease tends to be more aggressive and is associated with a higher incidence of relapse. While targeted therapies have improved treatment for other blood cancers, there have been few advances in AML.

[Read more](#)

### **Alliance, GNS Launch Big Data Initiative to Transform Metastatic Colorectal Cancer Treatment**

The Alliance for Clinical Trials in Oncology and GNS Healthcare (GNS), a leading precision medicine company that applies causal machine learning technology to match health interventions to individual patients and discover new target intervention pathways, have recently launched a big data initiative to identify patient subpopulations that may respond better to combination treatments for metastatic colorectal cancer. The collaboration leverages Reverse Engineering and Forward Simulation (REFS™), the patented GNS machine learning and simulation platform.

[Read more](#)

**Alliance for Clinical Trials in Oncology**

